Written Question·Department of Health and Social Care·UIN 109686

Blood Cancer: Medical Treatments

Tabled: 29 January 2026

Answered: 5 February 2026

Question

Mike Martin

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for N

Answer

Dr Zubir Ahmed

The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it can be recommended for routine National Health Service funding following a period of managed access through the Cance...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 109686) →